Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372987 | 1.00 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL31375366 | 1.00 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| Hydrochloric Acid SCHEMBL373321 | 0.99 | LMNA (0.55) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL7043759 | 0.92 | CHRNA7 (0.53) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL701090 | 0.86 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL7043317 | 0.84 | CHRNA7 (0.45) | CHRNA7CHRNB2CHRNA4LMNAALDH1A1 | |
| SCHEMBL6152811 | 0.84 | SMN1; SMN2 (0.70) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL6152809 | 0.84 | SMN1; SMN2 (0.70) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL700513 | 0.83 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL7042267 | 0.83 | TDP1 (0.44) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465501-B1 | Method for the preparation of (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide | ATTENUA INC (US) | 2016-10-05 | — | — | EP | claimed |
| EP-2431037-B1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | ATTENUA INC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2465501-B1 | Method for the preparation of (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide | ATTENUA INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20150045386-A1 | (2S,3R)-N-2-3-PYRIDINYLMETHYL-1-AZABICYCLO 2.2.2 OCT-3-YL BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | ATTENUA, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8846715-B2 | (2S,3R)-N-(2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140024673-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZYOFURN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT,INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024638-A1 | TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA | TARGACEPT, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2665478-A1 | TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA | Targacept, Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8541446-B2 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurn-2-carboxamide, novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2364150-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | Targacept Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7981906-B2 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010056622-A1 | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2185152-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | Targacept Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-2182949-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | Targacept Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090048290-A1 | 2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL-BENZYOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TRAMES BIO, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2009018505-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018511-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | CHRNA7 1/4885CHRNB2 6/4885CHRNA4 3/4885 |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885CHRNB2 17/4885CHRNA4 9/4885 |
| US-20140024673-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZYOFURN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | HCN3, HCN2, HCN1 | CHRNA7 39/4885CHRNB2 7/4885CHRNA4 23/4885 |
| US-20090048290-A1 | 2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL-BENZYOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | HCN3, HCN2, NTSR2 | CHRNA7 61/4885CHRNB2 7/4885CHRNA4 59/4885 |
| US-20150045386-A1 | (2S,3R)-N-2-3-PYRIDINYLMETHYL-1-AZABICYCLO 2.2.2 OCT-3-YL BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | HCN3, HCN2, NTSR2 | CHRNA7 80/4885CHRNB2 12/4885CHRNA4 76/4885 |
| US-20140024638-A1 | TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA | GRIN2C, GRIN2A, CHAT | CHRNA7 19/4885CHRNB2 15/4885CHRNA4 16/4885 |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | CHRNA7, CHRNA4, CHRNA2 | CHRNA7 1/4885CHRNB2 6/4885CHRNA4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.